2010
Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. Clinical Cancer Research 2010, 16: 2999-3010. PMID: 20404007, PMCID: PMC2887721, DOI: 10.1158/1078-0432.ccr-09-3233.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicBiomarkers, TumorCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansInsulin-Like Growth Factor IIOvarian NeoplasmsPaclitaxelPhosphorylationPrognosisProto-Oncogene Proteins c-aktPyrimidinesPyrrolesReceptor, IGF Type 1RNA, Small InterferingSignal TransductionConceptsEpithelial ovarian tumorsInsulin-like growth factorDisease-free survivalOvarian carcinoma cellsOvarian tumorsTaxol resistancePathway inhibitionIGF2 expressionOvarian cancerCarcinoma cellsExact testReduced disease-free survivalHuman epithelial ovarian tumorsCandidate prognostic biomarkerDrug-resistant ovarian carcinoma cellsUpregulation of IGF2Fisher's exact testIGF2 protein expressionOvarian cancer cellsDrug-resistant phenotypeHigh IGF2 expressionIGF receptor inhibitorsPathologic factorsTaxol-resistant cell linesCox regression
2006
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clinical Cancer Research 2006, 12: 298-304. PMID: 16397055, PMCID: PMC4039036, DOI: 10.1158/1078-0432.ccr-05-0229.Peer-Reviewed Original ResearchMeSH KeywordsAlkanesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCaspasesCell CycleCell Line, TumorDrug SynergismEnzyme ActivationFemaleHumansImmunohistochemistryLactonesMiceNeovascularization, PathologicOvarian NeoplasmsPaclitaxelPlatelet Endothelial Cell Adhesion Molecule-1PyronesXenograft Model Antitumor AssaysConceptsXenograft-bearing miceOvarian carcinomaTumor regressionCarcinoma cellsHuman ovarian cancer cellsOvarian carcinoma xenograftsOvarian cancer cellsCombination index methodOvarian carcinoma cellsCell cycle distributionTaxol efficacyCarcinoma xenograftsCD31 immunohistochemistryDrug combinationsImmunohistochemical analysisAnimal modelsSingle agentAntiangiogenic effectsLow dosesVivo modelNotable toxicityAntitumor efficacyDrug concentrationsCycle distributionMice